Spyre Therapeutics
SYRE
80.85
+0.74
+0.92%
Spyre Therapeutics
US · SYRE
#1646 by market cap
Listed 1970
80.85
+0.74
+0.92%
Live - 5344 symbols - heartbeat 25s ago
· 2026-10-08 07:00
Pre-market
80.50
-0.43%
After-hours
81.22
+0.46%
Overnight
79.62
-1.52%
- Market cap
- 7.13B
- P/E (TTM)i
- -40.83
- P/Bi
- 7.47
- EPSi
- -1.98
- Div yieldi
- 0.00%
- 52W posi
- 68%
Reader sentiment
Are you bullish or bearish on SYRE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 66.54, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Margins
Key ratios & quality
- Altman Z-Scorei
- 66.54
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 3.89M | 0 | 0 | 18.74M | 2.33M | 886.00K | 0 | 0 |
| Gross profit | -- | -- | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 12.63M | 15.73M | 21.84M | 27.32M | 28.53M | 39.95M | 45.78M | 47.91M |
| Research & development | 36.72M | 64.60M | 59.64M | 57.07M | 58.58M | 89.50M | 162.79M | 171.65M |
| Operating profit | -45.46M | -80.33M | -81.48M | -65.65M | -84.78M | -128.56M | -208.57M | -219.56M |
| Pretax profit | -44.35M | -78.25M | -80.89M | -65.66M | -83.95M | -338.82M | -207.97M | -155.22M |
| Tax | -- | 0 | 0 | 141.00K | -136.00K | -26.00K | 51.00K | -15.00K |
| Net profit | -44.35M | -78.25M | -80.89M | -65.80M | -83.82M | -338.79M | -208.02M | -155.20M |
| Basic EPS | -53 | -61 | -38 | -25 | -25 | -14 | -3 | -2 |
| Diluted EPS | -53.25 | -61.25 | -38.00 | -25.02 | -24.86 | -13.76 | -3.18 | -1.98 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- | -- |
| Gross profit | -- | -- | -- | -- | -- | -- |
| Selling & admin expenses | 11.94M | 11.79M | 11.64M | 12.53M | 15.23M | 16.14M |
| Research & development | 41.62M | 40.15M | 45.25M | 44.64M | 60.41M | 65.50M |
| Operating profit | -53.57M | -51.94M | -56.89M | -57.17M | -75.64M | -81.64M |
| Pretax profit | -44.79M | -36.72M | -11.18M | -62.53M | -69.01M | -36.20M |
| Tax | -15.00K | 0 | 0 | 0 | 0 | 0 |
| Net profit | -44.77M | -36.72M | -11.18M | -62.53M | -69.01M | -36.20M |
| Basic EPS | -1 | -1 | 0 | -1 | -1 | 0 |
| Diluted EPS | -0.60 | -0.60 | -0.18 | -0.70 | -0.74 | -0.43 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 76.67M | 74.51M | 149.79M | 98.89M | 62.26M | 341.53M | 608.47M | 777.78M |
| Cash & ST investments | 74.51M | 71.95M | 146.27M | 93.13M | 55.71M | 339.28M | 603.09M | 756.53M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 77.74M | 83.18M | 161.62M | 109.93M | 71.14M | 341.86M | 608.48M | 777.78M |
| Total current liabilities | 10.24M | 18.36M | 16.44M | 20.14M | 14.66M | 31.98M | 54.06M | 58.69M |
| Short-term debt | -- | 351.00K | 319.00K | 436.00K | 625.00K | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 10,311,000.00 | 23,102,000.00 | 21,786,000.00 | 25,985,000.00 | 20,839,000.00 | 157,843,000.00 | 90,680,000.00 | 62,545,000.00 |
| Total equity | 67.43M | 60.08M | 139.83M | 83.94M | 50.31M | 184.02M | 517.80M | 715.24M |
| Retained earnings | -116.86M | -195.12M | -276.01M | -341.81M | -425.62M | -764.41M | -972.43M | -1.13B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 569.77M | 538.83M | 504.60M | 777.78M | 763.95M | 1.17B |
| Cash & ST investments | 564.82M | 526.58M | 486.20M | 756.53M | 741.47M | 1.15B |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 569.78M | 538.83M | 504.60M | 777.78M | 763.95M | 1.17B |
| Total current liabilities | 70.68M | 83.06M | 46.27M | 58.69M | 85.16M | 63.30M |
| Short-term debt | -- | -- | -- | -- | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 87,168,000.00 | 83,059,000.00 | 49,504,000.00 | 62,545,000.00 | 93,142,000.00 | 71,862,000.00 |
| Total equity | 482.61M | 455.77M | 455.10M | 715.24M | 670.81M | 1.10B |
| Retained earnings | -1.02B | -1.05B | -1.07B | -1.13B | -1.20B | -1.23B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -32.19M | -65.69M | -75.78M | -53.72M | -80.14M | -99.91M | -157.41M | -169.25M |
| Depreciation & amortization | 293.00K | 418.00K | 996.00K | 1.58M | 1.96M | 744.00K | 0 | 0 |
| Free cash flow | -32.62M | -67.18M | -80.06M | -54.29M | -80.18M | -99.91M | -157.41M | -169.25M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 54.05M | 64.30M | 153.72M | 0 | 42.87M | 84.56M | 236.38M | 311.13M |
| Ending cash balance | 22.46M | 20.75M | 91.94M | 16.98M | 36.42M | 189.22M | 89.42M | 85.72M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -40.99M | -46.56M | -37.12M | -44.58M | -57.37M | -69.88M |
| Depreciation & amortization | -- | -- | -- | -- | -- | -- |
| Free cash flow | -40.99M | -46.56M | -37.12M | -44.58M | -57.37M | -69.88M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 0 | 0 | 0 | 311.13M | 9.75M | 435.24M |
| Ending cash balance | 48.49M | 81.66M | 64.90M | 85.72M | 97.19M | 162.01M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -75.32 | -122.74 | -80.93 | -58.81 | -124.87 | -1,371.79 | -82.84 | -33.69 |
| ROA %i | -66.28 | -97.26 | -66.09 | -48.46 | -92.58 | -164.06 | -31.47 | -22.39 |
| ROIC %i | -77.31 | -116.83 | -77.45 | -56.24 | -117.62 | -1,291.95 | -91.62 | -39.09 |
| 5-year avg ROE %i | -- | -- | -86.71 | -77.17 | -92.53 | -351.83 | -350.32 | -340.88 |
| EBIT margin %i | -1,169.32 | -- | -- | -350.33 | -3,640.23 | -14,510.61 | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 7.49 | 4.06 | 9.11 | 4.91 | 4.25 | 10.68 | 11.26 | 13.25 |
| Quick ratioi | 7.28 | 3.92 | 8.90 | 4.66 | 3.83 | 10.61 | 11.16 | 12.89 |
| Debt / assetsi | 0.00 | 6.09 | 3.37 | 4.60 | 6.51 | -- | -- | -- |
| LT debt / equityi | -- | 7.84 | 3.67 | 5.51 | 7.96 | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -13.87 | -- | -- | 68.92 | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -102.32 | -57.22 | -38.44 | -33.69 | -42.63 | -28.52 |
| ROA %i | -28.46 | -30.43 | -19.55 | -22.39 | -26.91 | -20.90 |
| ROIC %i | -114.14 | -63.92 | -48.43 | -39.09 | -48.66 | -33.23 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -- | -- | -- | -- | -- | -- |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 8.06 | 6.49 | 10.90 | 13.25 | 8.97 | 18.53 |
| Quick ratioi | 7.99 | 6.34 | 10.51 | 12.89 | 8.71 | 18.09 |
| Debt / assetsi | -- | -- | -- | -- | -- | -- |
| LT debt / equityi | -- | -- | -- | -- | -- | -- |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development of biopharmaceutical products for the treatment of patients with inflammatory bowel100.00%
Region
United States100.00%
Quote time 2026-10-08 07:00:13 · For reference only, not investment advice and not tailored to your situation.